Related Experiment Video
Updated: Jan 31, 2026

Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement
Published on: December 11, 2017
Statins Have No Role in Preventing the Progression of Aortic Valve Sclerosis
Jeong-Hun Seo1, Kwang-Jin Chun2, Bong-Ki Lee2
1Department of Internal Medicine, Kangwon National University Hospital, Chuncheon, Korea.
Insights
Statins do not impact the progression of aortic valve sclerosis (AVS). Further research is needed to understand AVS prognosis and management strategies.
Area of Science:
- Cardiology
- Vascular Medicine
- Pharmacology
Background:
- Aortic valve sclerosis (AVS) is characterized by leaflet thickening and increased echogenicity.
- Limited and inconsistent data exist regarding statin efficacy in AVS progression.
Purpose of the Study:
- To investigate the effect of statin treatment on the progression of aortic valve sclerosis (AVS).
Main Methods:
- Retrospective analysis of 541 patients with AVS, comparing statin-treated and non-statin-treated groups.
- AVS progression measured by the annual increase in peak aortic valve velocity.
- Follow-up duration averaged 24 months, with electrocardiography examinations at least 6 months apart.
Main Results:
- No significant difference in AVS progression rate between statin-treated and non-statin-treated groups (0.012 vs. 0.014 m/s/yr, p=0.956).
- Higher prevalence of hypertension, diabetes, ischemic heart disease, and stroke in the statin-treated group.
- Initial peak aortic jet velocity was a significant predictor of AVS progression (p=0.009).
Conclusions:
- Statins demonstrated no significant effect on the progression of aortic valve sclerosis.
- Further well-designed studies are required to establish the prognosis and optimal management of AVS.
Background:
Statins are thought to have little effect on the progression of aortic stenosis, but the data on their role in patients with aortic valve sclerosis (AVS) are limited and inconsistent.
Methods:
We retrospectively analyzed 541 consecutive patients (214 men, age: 70 ± 11 years) with AVS. Each patient underwent two or more electrocardiography examinations at least 6 months apart at Kangwon National University Hospital from August 2010 to August 2015. AVS is defined as irregular thickening of the leaflets, focal increases in echogenicity and minimal elevation of the peak aortic valve velocity (> 1.5 and < 2 m/s). The progression rate of AVS was expressed as the increase in peak velocity per year (m/s/yr).
Results:
The mean follow-up duration was 24.9 ± 13.3 months in the statin-treated group and 24.1 ± 12.4 months in the non-statin-treated group (p = 0.460). There were no differences between the statin-treated and non-statin-treated groups in mean age, gender or smoking status. Relative to the non-statin-treated group, a higher number of patients in the statin-treated group had hypertension, diabetes, ischemic heart disease, and stroke. The progression rate of AVS did not differ between the statin-treated and non-statin-treated groups (0.012 ± 0.340 m/s/yr vs. 0.014 ± 0.245 m/s/yr, p = 0.956). Multivariate analysis showed initial peak aortic jet velocity was significantly associated with AVS progression (β = 0.153, p = 0.009).
Conclusions:
Our study demonstrated that statins had no effect on the progression of AVS. However, well-designed studies are needed to define the prognosis and management of AVS.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Heart Valves
The AV valves prevent the backflow of blood from the ventricles to the atria during ventricular contraction. These valves function with the assistance of the chordae tendineae and papillary muscles. When the ventricles are relaxed, the chordae tendineae are slack, allowing blood to flow from the atria into the...
Cancer Prevention
Some...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Prevention of Further Absorption of Poison
Preventive Healthcare Services

